Strategies to prevent reaching end-stage kidney disease (ESKD) have focused on controlling hypertension, particularly with the use of renal-angiotensin system antagonists such as angiotensin-converting enzyme inhibitors (ACE-i) and angiotensin II receptor blockers (ARBs), as recommended by UK National Institute for Health and Care Excellence guidelines.14 The gene discussed is ACE; the disease is hypertensive disorder.